Evidence map›Paper›PMID 42262467›Full record

ArticleEJNMMI research2026

Experimental study of [

Xiujuan Zhao, Meng Dai, Tianyue Li, Nuo Li, Xiaolin Chen, Bo Dong, Yingxiao Guo, Mengyue Wei, Xinming Zhao, Jingmian Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiujuan Zhao *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Meng Dai *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Tianyue LiDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, People's Republic of China.
Nuo LiDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Xiaolin ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Bo DongDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Yingxiao GuoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Mengyue WeiDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China.
Jingmian ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No.12 Jiankang St, Chang' an District, Shijiazhuang, 050011, Hebei, China. jingmianzhang100@hebmu.edu.cn.ORCID http://orcid.org/0009-0009-1676-5896

Funding

The Hebei Natural Science Foundation in China H2023206016
6 · The paper itself

Abstract

backgroundRadiolabeled heterodimeric peptides have emerged as a highly promising targeting strategy for PET imaging due to their superior binding properties. The Human epidermal growth factor receptor 2 (HER2)- and Arg-Gly-Asp (RGD)-targeting moieties bind to HER2 and integrin αvβ3, respectively, receptors that are both overexpressed in many different types of tumors. This study focuses on the synthesis and evaluation of the heterodimeric radioligand [

resultsThe heterodimeric radiopeptide was successfully synthesized and radiolabeled with

conclusion[

Indexed as

Breast cancerDual-receptor targetedHER2Integrin αvβ3PET/CT

Identifiers

PMID42262467
PMCPMC13473053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.